

# Switzer Small and Microcap -Virtual Investor Day, December 2020

ASX:IBX

www.imagionbiosystems.com

# DISCLAIMER



This investor presentation (**Presentation**) has been prepared by Imagion Biosystems Limited (**Imagion** or the **Company**). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information. Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.

IMAGIONBIOSYSTEMS.COM | 2

# IMAGION BIOSYSTEMS AT-A-GLANCE



New medical imaging technologies for the early detection of cancer

Imagion Biosystems ASX:IBX Australian Medical Device Company developing bio-safe medical imaging technologies.

Market cap: ~\$136.75 million Cash at 30 Sep 2020: \$8.3M (an additional \$6 million raised 23/11/20)

Listed on the ASX: June 2017 R&D operations: San Diego Registered office: Melbourne

Recent Milestones: <u>Nov 2020</u> \$6 Million placement <u>Oct 2020</u> HREC approval received for Phase I Study <u>May 2020</u> Research Collaboration with Siemens <u>July 2019</u> Received "*Breakthrough Device*" designation by U.S. FDA

www.imagionbiosystems.com

- Innovative **medical imaging** using **magnetic nanoparticles** to identify and stage cancer early
- Proprietary MagSense<sup>™</sup> technology is non-invasive and provides more specific & sensitive detection for cancer than current imaging technologies
- Multiple commercial opportunities:
  - Proprietary MagSense<sup>™</sup> imaging technology
  - Magnetic Resonance Imaging (MRI) contrast agent
  - Therapy and/or drug delivery
- MagSense<sup>™</sup> technology complements existing imaging and is more cost effective than many existing imaging technologies
- First-in-human studies on-track for 2020 targeting metastatic breast cancer



Patents are already issued, or are pending, in all the major markets, making the lions share of the global markets available for commercialization. *Patents are valid through 2029.* 

IMAGIONBIOSYSTEMS.COM | 3

### A GROWING GLOBAL HEALTH PROBLEM

1 in 3 people are affected by cancer



#### Each year cancer kills 9 million people

\$100B spent annually to diagnose or detect cancer, yet cancer continues to be a leading cause of mortality and morbidity

\* Source: Transparency Market Research - Global Cancer Diagnostics Market 2014-2020

# CLEAR UNMET MEDICAL NEED



50 years since last new imaging technology was introduced



#### X-RAY (MAMMOGRAPHY) 1913

- Best used for finding structural anomalies (e.g. broken bones), and chest X-rays
- Mammography used for screening for breast cancer
- Risks include exposure to carcinogenic ionizing radiation



ULTRASOUND 1956

- Inexpensive and fast method to look at human organs and areas of inflammation
- Used to guide needle biopsies and detect ovarian cancer
- Poor sensitivity to detecting tumors – tumours must be billions of cells in size



#### MAGNETIC RESONANCE (MRI) 1971

- Best for imaging soft tissue including ligaments, tendons, the brain, and many internal organs
- Used for detecting brain cancers
- Scans can be long and clostrophobic



COMPUTED TOMOGRAPHY (CT) 1972

- Better for imaging the lungs than MRI
- Scan times shorter than
   MRI
- Used in staging solid tumors, guiding biopsy
- Exposes patients to carcinogenic ionizing radiation



#### POSITRON EMISSION TOMOGRAPHY (PET) 1973

- Can be expensive and poorer resolution than MRI or CT
- Better sensitivity for identification of metastatic lesions
- Subject to significant off-target and high background signals
- Requires use of radioactive tracer exposing patients to radiation

#### "Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor."

Journal of Clinical Oncology, 2008 New Technologies for Human Cancer Imaging Vol 26 No 24

# MEDICAL IMAGING BREAKTHROUGH

MagSense<sup>™</sup> Technology will transform cancer diagnosis

- Non-invasive a safe and non-surgical solution to detect cancer
- No radioactivity uses bio-safe magnetic nanoparticles to "tag" cancer cells
- Platform technology can be used for many cancers as well as other diseases, e.g. infection and cardiovascular
- **Proprietary** patent issued in most major global markets
- **Breakthrough** technical feasibility and safety profile vetted, designated as a "breakthrough device" by FDA
- First indication metastatic breast cancer, provides shortest path to commercialization
- First-in-human ready for clinical studies a catalyst for valuation and partnering





# IMPROVING OUTCOMES

#### Better sensitivity could mean earlier detection

MagSense<sup>™</sup> technology is expected to have sensitivity comparable to PET without use of radioactivity, making it better for routine use in early detection and resulting in more successful treatments and patient outcomes.



\* Source: SEER Cancer statistics, National Cancer Institute, 2013

#### "Early detection of many diseases, particularly cancers, is key to successful treatment."

Chemical Reviews 2015 Nanoparticles in Medicine Vol 115





#### IMAGIONBIOSYSTEMS.COM | 8

### TRANSFORMATIVE FOR MEDICAL IMAGING

Designated by FDA as a "Breakthrough Device"

#### The MagSense<sup>™</sup> HER2 Metastatic Breast Cancer Test

- Works within current standard cancer diagnosis and staging protocols.
- Replaces current non-functional imaging such as MRI or ultrasound used to assess for enlarged lymph nodes but which cannot determine if tumor cells are present.
- Would eliminate unnecessary biopsies for patients that do not have metastatic spread to the lymph nodes.
- Would reduce incidence of lymphedema and associated morbidity.

The MagSense™ system and test has been designated by the FDA as a **Breakthrough Device** - reserved for products that provide for more effective treatment or diagnosis.





MagSense<sup>™</sup> nanoparticle reagent given to patient.





# BROAD COMMERCIAL APPLICABILITY

Can be used for many types of cancer and at multiple stages of diagnosis



- Are bio-functionalized to ensure high specificity for targeting different types of cancers, or other diseases.
- Can be used at multiple stages including primary diagnosis, staging, and monitoring the effectiveness of therapy.
- Are compatible with Imagion's proprietary MagSense technology and with existing installed MRI systems as an MRI contrast agent.
- Uses known safe materials, including iron-oxide cores which are already cleared for multiple clinical uses including therapeutic applications.

#### **MULTIPLE CLINICAL TARGETS**





# COMPELLING BUSINESS MODEL

#### Proprietary consumable drives growth & profitability

US Patent 9095270 - Detection, measurement, & imaging of cells such as cancer & other biological substances using targeted nanoparticle & magnetic properties thereof



Lower Cost Capital Sale than MRI or CT ~ \$500K USD Does not require installation expense of shielded room Licensing or Commercial Partnership with Medical Imaging Player(s)

Imagion receives licensing/milestone fees and royalties on sales



Each Cancer Test Billable ~\$1500 USD\*

80% Gross Margin

Annual Revenue per Installed MagSense™ System \$500K - \$2M USD

\* Company estimate based on current procedures. Reimbursement code and pricing has not been defined.

# ACHIEVEMENTS AND NEXT STEPS

Phase I Study for HER2 Metastatic Breast Cancer

#### Achievements in 2019-20

- ✓ GLP Toxicity study completed
- ✓ FDA "Breakthrough Device" designation
- Scientific Advisory Board established
- ✓ Collaboration with Siemens in MRI
- ✓ GMP production for Phase I Study
- ✓ HREC Approval in Australia



\* Projected dates/targets are indicative only, and subject to change.

# A PLATFORM FOR GROWTH

Significant opportunities in biomedical applications of magnetic nanoparticles



# INVESTMENT RATIONALE



Strategic plan provides path to future products & shareholder value



#### STAGING BREAST CANCER

Reduce unnecessary surgery

\$700M

TUMOR DETECTION

Breast, prostate, lung & ovarian

\$7B

MRI CONTRAST

Safer alternative to current product, Gadolinium

>\$3B

TREATMENT MONITORING

Monitor tumor size and adjust treatment accordingly

>\$2B

**Addressable Markets** 

DOCTORS OFFICE

Hand-held MagSense instrument

>\$14B

#### DETECTION & THERAPY

Provide both detection & delivery of therapy

>\$140B

### CAPITAL STRUCTURE

#### *No debt, one class of common stock*





#### Share price – Last 12 months

IMAGIONBIOSYSTEMS.COM | 14

### INVESTMENT HIGHLIGHTS



# LARGE OPPORTUNITY \$100B cancer diagnostic market Growing 7% annually Medical imaging commands largest share Huge medical need for early diagnosis

# UNIQUE TECHNOLOGY

New form of medical imaging Molecularly specific & non-invasive More sensitive than current methods Protected by eight patents

S
COMMERCIAL STRATEGY
\$2B initial market focus
Applies to many types of cancer
Printer-ink revenue model
Potential for therapeutics & research markets



#### **READY TO ENTER THE CLINIC**

Technical feasibility demonstrated

Safety profile of technology vetted

FDA "breakthrough device" designation

First-in-human data readout expected in 2020

# INAGION BIOSYSTEMS

**Contact:** www.imagionbiosystems.com info@imagionbio.com ASX: IBX